India’s premier medical research body, the Indian Council of Medical Research (ICMR), has issued new guidance encouraging that clinical trials be designed and analyzed using data representative of Indian populations and body types, according to multiple reports.
The mandate aims to ensure that medical evidence used to guide treatment decisions is based on India-specific physiological, genetic, and lifestyle factors rather than relying primarily on foreign data. Public health experts and regulators say this could help improve the relevance and effectiveness of medical interventions for chronic and lifestyle diseases prevalent in India.
Under the recent mandate, the ICMR recommends that clinical trials conducted in India develop protocols that prioritize:
Recruitment of participants who reflect the diversity of Indian body types and genetic backgrounds,
Consideration of population-specific disease patterns, and
Analysis focused on outcomes relevant to Indian clinical practice.
The guidance does not ban data from international trials, but it emphasizes that studies should generate India-centric evidence to inform clinical decisions and regulatory approvals.
See also: NMC and ICMR Set to Launch PhD Programs to Boost Clinical Research
ICMR officials have highlighted that many treatments and lifestyle disease interventions currently used in India are supported by global studies that may not fully account for India’s unique genetic, dietary, and environmental factors. The new mandate seeks to address this gap by prioritizing home-grown clinical evidence.
Clinical trials provide the scientific basis for determining whether medicines, devices, or interventions are safe and effective. Trial outcomes can be influenced by factors such as:
Genetics: Variations in DNA that affect drug metabolism and disease risk.
Body composition: Differences in height, weight, and fat distribution that impact dosing and response.
Diet and lifestyle: Nutritional patterns that influence disease development and drug interaction.
Environmental exposures: Urbanization, pollution, and regional risk factors affecting disease prevalence.
ICMR’s directive aims to ensure that medical evidence generated in India reflects the local population’s biology and health characteristics, potentially improving treatment outcomes for conditions such as diabetes, heart disease, hypertension, and other lifestyle diseases.
India bears a significant burden from non-communicable diseases (NCDs) such as cardiovascular disease, diabetes, and cancer. These conditions are influenced by a combination of genetic predisposition, urban lifestyle changes, and dietary patterns.
Evidence tailored to Indian populations may help clinicians adapt dosing regimens and therapeutic strategies that align more closely with patient needs.
The mandate encourages collaboration between academic institutions, hospitals, and industry sponsors to invest in clinical trials that capture real-world variations among Indian patients. It also underscores the need for transparent reporting and data sharing so that evidence can inform national clinical guidelines.
Increased investment in trial infrastructure, training for investigators, and community engagement are expected to support implementation of the new mandate.
(Rh)
